The effect of neuroleptic treatments on executive function and symptomatology in schizophrenia: A 1-year follow up study

Schizophrenia Research

Volumn 80, Issue 1, 2005, Pages 99-106

  Rémillard, Sophie ^a   Pourcher, Emmanuelle ^b   Cohen, Henri ^a  

^a UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

^b Quebec Memory and Motor Skills Disorder Research Center   (Canada)

Author keywords

Executive function; Haloperidol; Long term treatment; Risperidone; Schizophrenia; Symptomatology

Indexed keywords

HALOPERIDOL; NEUROLEPTIC AGENT; RISPERIDONE;

ADULT; AGE DISTRIBUTION; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EDUCATION; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; HEALTH STATUS; HUMAN; MALE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOPHRENIA; SKILL; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY; TASK PERFORMANCE; WISCONSIN CARD SORTING TEST;

ADULT; ANTIPSYCHOTIC AGENTS; BRAIN; COGNITION; COGNITION DISORDERS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; RISPERIDONE; SCHIZOPHRENIA;

EID: 27744561733     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2005.07.026     Document Type: Article

References (43)

1. J. Addington, and D. Addington Neurocognitive and social functioning in schizophrenia: a 2.5 year follow-up study Schizophrenia Research 44 2000 47 56
2. M.R. Basso, H.A. Nasrallah, S.C. Olson, and R.A. Bornstein Neuropsychological correlates of negative, disorganized and psychotic symptoms in schizophrenia Schizophrenia Research 31 1998 99 111
3. E.A. Berg A simple objective test for measuring flexibility in thinking Journal of General Psychology 39 1948 15 22
4. K.F. Berman, J.L. Ostrem, C. Randolph, J. Gold, T.E. Goldberg, R. Coppola, R.E. Carson, P. Herscovitch, and D.R. Weinberger Physiological activation of cortical networks during performance of the Wisconsin Card Sorting Test: a positron emission tomography study Neuropsychologia 33 1995 1027 1046
5. I. Berman, B. Viegner, A. Mason, E. Allan, D. Pappas, and A.I. Green Differential relationships between positive and negative symptoms and neuropsychological deficits in schizophrenia Schizophrenia Research 25 1997 1 10
6. R.M. Bilder, R.S. Goldman, J. Volavka, P. Czobor, M. Hoptman, B. Sheitman, J.-P. Lindenmayer, L. Citrome, J. McEvoy, M. Kunz, M. Chakos, T.B. Cooper, T.L. Horowitz, and J.A. Lieberman Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder American Journal of Psychiatry 159 2002 1018 1028
7. G. Bondolfi, H. Dufour, M. Patris, J.P. May, U. Billeter, C.B. Eap, and P. Baumann Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study American Journal of Psychiatry 155 1998 499 504
8. A. Borkowska, A. Araszkiewicz, A. Rajewski, and J.K. Rybakowski Risperidone treatment of schizophrenia: improvement in psychopathology and neuropsychological tests Neuropsychobiology 46 2002 85 89
9. J. Carman, J. Peuskens, and A. Vangeneugden Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis International Clinical Psychopharmacology 10 1995 207 213
10. A.A. Collins, G.J. Remington, K. Coulter, and K. Birkett Insight, neurocognitive function and symptom clusters in chronic schizophrenia Schizophrenia Research 27 1997 37 44
11. R.R. Conley, and R. Mahmoud A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder American Journal of Psychiatry 158 2001 765 774
12. M.J. Cuesta, V. Peralta, and A. Zarzuela Effects of olanzapine and other neuroleptics on cognitive function in chronic schizophrenia: a longitudinal study Schizophrenia Research 48 2001 17 28
13. J.I. Friedman, H. Temporini, and K.L. Davis Pharmacologic strategies for augmenting cognitive performance in schizophrenia Biological Psychiatry 45 1999 1 16
14. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects Archives of General Psychiatry 49 1992 538 544
15. M.F. Green What are the functional consequences of neurocognitive deficits in schizophrenia? American Journal of Psychiatry 153 1996 321 330
16. M.F. Green, S.R. Marder, S.M. Glynn, S.R. McGurk, W.C. Wirshing, D.A. Wirshing, R.P. Liberman, and J. Mintz The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone Biological Psychiatry 51 2002 972 978
17. P.D. Harvey, and R.S.E. Keefe Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment American Journal of Psychiatry 158 2001 176 184
18. P.D. Harvey, M. Parrella, L. White, R.C. Mohs, M. Davidson, and K.L. Davis Convergence of cognitive and adaptive decline in late-life schizophrenia Schizophrenia Research 35 1999 77 84
19. P.D. Harvey, M.F. Green, S.R. McGurk, and H.Y. Meltzer Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study Psychopharmacology 169 2003 404 411
20. R.K. Heaton, C.J. Chelune, J.L. Talley, G.G. Kay, and G. Curtiss Wisconsin Card Sorting Test Manual-Revised and Expanded 1993 Psychological Assessment Resources Odessa, FL
21. A. Heinz, M.B. Knable, R. Coppola, J.G. Gorey, D.W. Jones, K.-S. Lee, and D.R. Weinberger Psychomotor slowing, negative symptoms and dopamine receptor availability-an IBZM SPECT study in neuroleptic-treated and drug-free schizophrenic patients Schizophrenia Research 31 1998 19 26
22. G. Heydebrand, M. Weiser, J. Rabinowitz, A.L. Hoff, L.E. DeLisi, and J.G. Csernansky Correlates of cognitive deficits in first episode schizophrenia Schizophrenia Research 68 2004 1 9
23. A.L. Hoff, M. Sakuma, M. Wieneke, R. Horon, M. Kusher, and L.E. DeLisi Longitudinal neuropsychological follow-up study of patients with first-episode schizophrenia American Journal of Psychiatry 156 1999 1336 1341
24. K.S. Hong, J.G. Kim, M.S. Koo, J.H. Kim, D. Lee, and E. Kim Effects of risperidone on information processing and attention in first-episode schizophrenia Schizophrenia Research 53 2002 7 16
25. C. Hughes, V. Kumari, W. Soni, M. Das, B. Binneman, S. Drozd, S. O'Neil, V. Mathew, and T. Sharma Longitudinal study of symptoms and cognitive function in chronic schizophrenia Schizophrenia Research 59 2002 137 146
26. 2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study Life Sciences 57 1995 103 107
27. 2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia American Journal of Psychiatry 157 2000 514 520
28. S. Kasper, and E. Resinger Cognitive effects and antipsychotic treatment Psychoneuroendocrinology 28 2003 27 38
29. S.R. Kay, L.A. Opler, and J.P. Lindenmayer The Positive and Negative Syndrome Scale (PANSS): rationale and standardization British Journal of Psychiatry 155 1989 59 67
30. S. Marenco, R. Coppola, D.G. Daniel, J.R. Zigun, and D.R. Weinberger Regional cerebral blood flow during the Wisconsin Card Sorting Test in normal subjects as studied by xenon-133 dynamic SPECT: comparison of absolute values, percent distribution values, and covariance analysis Psychiatry Research 50 1993 177 192
31. H.Y. Meltzer, and S.R. McGurk The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia Schizophrenia Bulletin 25 1999 233 255
32. Y. Okubo, T. Shuhara, K. Suzuki, K. Kobayashi, O. Inoue, O. Terasaki, Y. Someya, T. Sassa, Y. Sudo, E. Matsushima, M. Iyo, Y. Tateno, and M. Toru Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET Nature 385 1997 634 636
33. J. Peuskens Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol British Journal of Psychiatry 166 1995 712 733
34. S.E. Purdon, B.D.W. Jones, E. Stip, A. Labelle, D. Addington, S.R. David, A. Breier, and G.D. Tollefson Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol Archives of General Psychiatry 57 2000 249 258
35. J. Rabinowitz, and M. Davidson Risperidone versus haloperidol in long-term hospitalized chronic patients in a double blind randomized trial: a post hoc analysis Schizophrenia Research 50 2001 89 93
36. L.M. Ritter, J.H. Meador-Woodruff, and G.W. Dalack Neurocognitive measures of prefrontal cortical dysfunction in schizophrenia Schizophrenia Research 68 2004 65 73
37. A. Rossi, F. Mancini, P. Stratta, P. Matei, R. Gismondi, F. Pozzi, and M. Cassachia Risperidone, negative symptoms and cognitive deficit in schizophrenia: an open study Acta Psychiatrica Scandinavica 95 1997 40 43
38. A.J. Saykin, D.L. Shtasel, R.E. Gur, D.B. Kester, L.H. Mozley, P. Stafiniak, and R.C. Gur Neuropsychological deficits in neuroleptic naïve patients with first-episode schizophrenia Archives of General Psychiatry 51 1994 124 131
39. E. Stip, S. Chouinard, and L.J. Boulay On the trail of a cognitive enhancer for the treatment of schizophrenia Progress in Neuro-Psychopharmacology & Biological Psychiatry 29 2005 219 232
40. D.I. Velligan, R.K. Mahurin, P.L. Diamond, B.C. Hazleton, S.L. Eckert, and A.L. Miller The functional significance of symptomatology and cognitive function in schizophrenia Schizophrenia Research 25 1997 21 31
41. L.N.P. Voruganti, R.J. Heslegrave, and A.G. Awad Neurocognitive correlates of positive and negative syndromes in schizophrenia Canadian Journal of Psychiatry 42 1997 1066 1071
42. D.R. Weinberger, K.F. Berman, and R.F. Zec Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia: I. Regional cerebral blood flow (rCBF) evidence Archives of General Psychiatry 43 1986 114 125
43. Y.-C. Yen, F.-W. Lung, and M.-Y. Chong Adverse effects of risperidone and haloperidol treatment in schizophrenia Progress in Neuro-Psychopharmacology & Biological Psychiatry 28 2004 285 290